We want to transform healthcare by developing novel vaccines that are lifesaving and improving quality of life around the world.

We are a clinical-stage biotechnology company listed on NASDAQ First North Growth Market Sweden with a resolute vision of the future:

Developing innovative vaccines for a healthier world

Two mature forensic scientists working together on a new research in a laboratory.
S1080979

Advancing groundbreaking vaccines through our exclusive technological platform

By leveraging our proprietary ExpreS2 protein expression system, we are playing a key role in the development of cutting-edge vaccines to address some of the worst and most impactful diseases.

Our vaccine candidates aim at bringing hope to millions by preventing infectious diseases and treating cancer, saving lives, and fostering resilient communities.

Latest news

ExpreS2ion resolves on a directed issue of units to guarantors in connection with the completed rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. FOR…

Read more

ExpreS2ion announces U.S. patent issue notification for glyco-engineered immunization antigens

Hørsholm, Denmark, 3 July 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") a late preclinical stage biotechnology company with a focused portfolio of vaccine candidates targeting infectious diseases and cancer, today announced it has received an Issue Notification from the United States Patent and Trademark Office (USPTO) for the patent "Glyco-Engineered Immunization…

Read more

ExpreS2ion announces final outcome of its rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. FOR…

Read more